Evergreen Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.67M | Sell |
43,786
-130,740
| -75% | -$6.19M | 0.04% | 357 |
|
|
2025
Q4 | $8.88M | Sell |
174,526
-17,902
| -9% | -$915K | 0.2% | 122 |
|
|
2025
Q3 | $10.7M | Buy |
192,428
+21,080
| +12% | +$1.23M | 0.25% | 101 |
|
|
2025
Q2 | $11.8M | Buy |
171,348
+19,955
| +13% | +$1.36M | 0.36% | 77 |
|
|
2025
Q1 | $10.7M | Buy |
151,393
+119,688
| +378% | +$9.89M | 0.36% | 73 |
|
|
2024
Q4 | $2.73M | Buy |
31,705
+2,148
| +7% | +$232K | 0.09% | 213 |
|
|
2024
Q3 | $3.52M | Buy |
29,557
+250
| +0.9% | +$33.3K | 0.12% | 190 |
|
|
2024
Q2 | $4.18M | Buy |
29,307
+1,710
| +6% | +$227K | 0.15% | 157 |
|
|
2024
Q1 | $3.57M | Buy |
27,597
+145
| +0.5% | +$17.3K | 0.13% | 171 |
|
|
2023
Q4 | $2.84M | Sell |
27,452
-313
| -1% | -$31K | 0.12% | 194 |
|
|
2023
Q3 | $2.52M | Buy |
27,765
+397
| +1% | +$35K | 0.11% | 198 |
|
|
2023
Q2 | $2.21M | Buy |
27,368
+564
| +2% | +$46.1K | 0.09% | 206 |
|
|
2023
Q1 | $2.14M | Buy |
26,804
+2,736
| +11% | +$194K | 0.1% | 206 |
|
|
2022
Q4 | $1.63M | Sell |
24,068
-628
| -3% | -$36.8K | 0.08% | 230 |
|
|
2022
Q3 | $1.23M | Buy |
24,696
+798
| +3% | +$42.7K | 0.06% | 242 |
|
|
2022
Q2 | $1.33M | Buy |
23,898
+3,076
| +15% | +$171K | 0.07% | 231 |
|
|
2022
Q1 | $1.16M | Buy |
20,822
+1,334
| +7% | +$68.5K | 0.05% | 270 |
|
|
2021
Q4 | $1.09M | Buy |
19,488
+588
| +3% | +$31.9K | 0.04% | 272 |
|
|
2021
Q3 | $907K | Buy |
18,900
+582
| +3% | +$28.1K | 0.04% | 293 |
|
|
2021
Q2 | $767K | Buy |
18,318
+1,078
| +6% | +$41.8K | 0.04% | 291 |
|
|
2021
Q1 | $581K | Buy |
17,240
+2,028
| +13% | +$72.2K | 0.03% | 304 |
|
|
2020
Q4 | $531K | Buy |
15,212
+1,100
| +8% | +$38K | 0.03% | 280 |
|
|
2020
Q3 | $490K | Buy |
14,112
+492
| +4% | +$16.4K | 0.03% | 265 |
|
|
2020
Q2 | $446K | Sell |
13,620
-3,184
| -19% | -$102K | 0.03% | 254 |
|
|
2020
Q1 | $506K | Sell |
16,804
-1,578
| -9% | -$47K | 0.05% | 217 |
|
|
2019
Q4 | $532K | Sell |
18,382
-216
| -1% | -$5.98K | 0.04% | 243 |
|
|
2019
Q3 | $481K | Buy |
18,598
+4,632
| +33% | +$117K | 0.04% | 230 |
|
|
2019
Q2 | $356K | Buy |
13,966
+2,644
| +23% | +$65.3K | 0.03% | 280 |
|
|
2019
Q1 | $296K | Sell |
11,322
-1,472
| -12% | -$36.2K | 0.03% | 289 |
|
|
2018
Q4 | $295K | Buy |
12,794
+234
| +2% | +$5.2K | 0.03% | 273 |
|
|
2018
Q3 | $296K | Buy |
12,560
+278
| +2% | +$6.78K | 0.03% | 291 |
|
|
2018
Q2 | $283K | Buy |
12,282
+208
| +2% | +$4.94K | 0.03% | 288 |
|
|
2018
Q1 | $297K | Buy |
+12,074
| New | +$317K | 0.03% | 268 |
|
Other funds holding NVO
DAM
F
Evergreen Capital Management's NVO Position: Q1 2026 in Review
Evergreen Capital Management reduced its Novo Nordisk (NVO) stake by 75% in Q1 2026, selling an estimated $6.19M and leaving 43,786 shares worth $1.67M. The position accounts for 0.04% of the portfolio, ranked #357.
Evergreen Capital Management first reported a position in NVO in Q1 2018 and has held it in 33 quarters since. The position peaked at $11.8M in Q2 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Evergreen Capital Management held 43,786 shares of Novo Nordisk worth $1.67M as of Q1 2026.
- Evergreen Capital Management sold 130,740 Novo Nordisk shares in Q1 2026, an estimated $6.19M.
- Novo Nordisk made up 0.04% of Evergreen Capital Management's portfolio in Q1 2026, its #357 holding.
- Evergreen Capital Management first reported a position in Novo Nordisk in Q1 2018 and has held it in 33 quarters since.
- Evergreen Capital Management's Novo Nordisk position peaked at $11.8M in Q2 2025.
- 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Evergreen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.